Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01383603
Recruitment Status : Completed
First Posted : June 28, 2011
Last Update Posted : June 11, 2014
Adiga Life Sciences, Inc.
Information provided by (Responsible Party):
Circassia Limited

Brief Summary:

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel, synthetic, allergen derived peptide desensitising vaccine currently being developed for treatment of cat allergy.

At present, the efficacy of immunotherapy (peptide or otherwise) can only be established at the conclusion of therapy. No reliable predictive biomarkers of clinical efficacy currently exist. Identification of surrogate biomarkers of clinical efficacy, would facilitate clinical development of peptide immunotherapy vaccines, in addition to providing an improved understanding of the underlying molecular mechanisms of efficacy, thus providing new leads for therapeutic intervention.

Condition or disease Intervention/treatment Phase
Cat Allergy Biological: Cat-PAD Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Study Start Date : October 2011
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Cat-PAD Biological: Cat-PAD
Intradermal injection 1 x 4 administrations 4 weeks apart

Primary Outcome Measures :
  1. Identification of a change in gene expression over the course of and potentially attributable to Cat-PAD treatment. [ Time Frame: 6 months following treatment ]

Secondary Outcome Measures :
  1. Symptom scores for ocular and nasal symptoms [ Time Frame: 4 weeks following treatment ]
  2. Interleukin production and eosinophil level changes [ Time Frame: 4 weeks following treatment ]
  3. Functional genomic changes [ Time Frame: 4 weeks following treatment ]
  4. Changes in urine metabolomic profiles [ Time Frame: 4 weeks following treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female, aged 18-65 years.
  • Weight >50 kg.
  • A minimum 1-year documented history of rhinoconjunctivitis on exposure to cats.
  • Positive skin prick test to cat allergen.
  • Subjects must have regular exposure to a cat in their normal living or working circumstances throughout the course of the study.
  • Minimum qualifying rhinoconjunctivitis symptom scores

Exclusion Criteria:

  • History of asthma
  • History of anaphylaxis to cat allergen
  • History of allergen immunotherapy in the previous 10 years, or in the previous 3 years for pre-seasonal immunotherapy treatments
  • History of any significant disease or disorder (e.g. autoimmune, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment, severe atopic dermatitis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01383603

Canada, Ontario
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L9C3N6
Sponsors and Collaborators
Circassia Limited
Adiga Life Sciences, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Circassia Limited Identifier: NCT01383603     History of Changes
Other Study ID Numbers: RES-004
First Posted: June 28, 2011    Key Record Dates
Last Update Posted: June 11, 2014
Last Verified: June 2014

Keywords provided by Circassia Limited:
Cat Allergy